4.5 Review

European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice

Journal

CONTACT DERMATITIS
Volume 73, Issue 4, Pages 195-221

Publisher

WILEY-BLACKWELL
DOI: 10.1111/cod.12432

Keywords

contact allergy; guideline; patch testing; review

Funding

  1. IFRA
  2. RIFM
  3. Novartis
  4. GSK
  5. Vifor
  6. Intendis - Bayer
  7. Uriach Pharma
  8. Genentech
  9. Menarini
  10. MSD
  11. Almirall
  12. Biogen-Idec
  13. Galderma
  14. SmartPractice
  15. Almirall Hermal
  16. GlaxoSmithKline
  17. Basilea
  18. Zilverlon
  19. Stallergenes
  20. Unilever
  21. l'ARCAA

Ask authors/readers for more resources

The present guideline summarizes all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed-type hypersensitivity skin and mucosal conditions. Sections with brief descriptions and discussions of different pertinent topics are followed by a highlighted short practical recommendation. Topics comprise, after an introduction with important definitions, materials, technique, modifications of epicutaneous testing, individual factors influencing the patch test outcome or necessitating special considerations, children, patients with occupational contact dermatitis and drug eruptions as special groups, patch testing of materials brought in by the patient, adverse effects of patch testing, and the final evaluation and patient counselling based on this judgement. Finally, short reference is made to aspects of (continuing) medical education and to electronic collection of data for epidemiological surveillance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available